Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$8.30
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.30
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.63
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.75M
Market Cap
$804.36M
Enterprise Value$1.06B
Total Cash (Recent Filing)$200.97M
Total Debt (Recent Filing)$96.52M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding99,303,260
10 Day Avg. Volume2,307,704
30 Day Avg. Volume1,751,497
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue10.66
Enterprise Value/Gross Profit13.83
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
$28.33Price Target Upside241.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$146.81M
Bulls Say, Bears Say
Bulls Say
Healthy Product-level Gross MarginSustained gross margins near 76% indicate strong unit economics for neffy. High product-level margins provide structural room to absorb commercial and payer discounts, support reinvestment in sales and marketing, and materially improve operating leverage as volume scales and refill dynamics mature.
Rapid Commercial Adoption And Installed Base GrowthTriple year-over-year prescription volume and a growing installed base (~120k patients) show durable product adoption in a refill-driven category. A larger recurring patient base supports predictable refill revenue, improves unit economics over time and creates stickiness with prescribers and payors.
Regulatory Approvals Broaden Market AccessLabel expansion and approvals in Canada and the EU materially expand the addressable market and permit partner-led launches. Pediatric access and international authorizations create multi-geography revenue optionality and reduce reliance on a single payor market for long-term growth.
Bears Say
Deep Negative Operating Cash FlowPersistent negative operating cash flow (~-$175M TTM) reflects heavy cash burn to fund commercialization. Even with $201M cash, continued high burn raises refinancing risk if revenue ramps slower than planned, making execution on mid-2027 breakeven guidance critical to avoid dilution.
Large Net Losses And Negative ReturnsVery large trailing losses and sharply negative margins indicate the company remains structurally unprofitable. Declining shareholder equity and negative ROE reduce financial flexibility and increase sensitivity to slower revenue or higher-than-expected commercial costs.
Payer Friction, High Gross-to-net And Prescription AbandonmentMaterial prior-authorization barriers, elevated gross-to-net deductions and ~22–23% abandonment structurally compress net revenue and limit realized demand. These durable access and conversion frictions slow monetization of written prescriptions and require sustained payer, point-of-sale, and affordability efforts.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.63 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $804.36M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on May 15, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.516 by -$0.094.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,303,260 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.516. Following the earnings report the stock price went down -6.486%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.33 (241.37% Upside)
$28.33 (241.37% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 339.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.21%
12-Months-Change
Fundamentals
Return on Equity
-153.61%
Trailing 12-Months
Asset Growth
-12.14%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress (robust YoY prescription and revenue growth, regulatory approvals, expanded coverage and new affordability programs), backed by a healthy cash balance and a clear plan to scale through the back-to-school season and refill cycles. However, execution risks remain: significant SG&A spend and cash burn, prior-authorization friction that still limits access for a meaningful portion of covered lives, notable prescription abandonment, and uncertainty around timing of key payer decisions (e.g., CVS Caremark). On balance, the positives around growth, access expansion, regulatory wins and commercial initiatives outweigh the operational challenges, but the company remains execution- and timing-dependent over the coming quarters.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$28.33
▲(241.37% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
50.06% Insiders
6.93% Mutual Funds
0.36% Other Institutional Investors
33.30% Public Companies and
Individual Investors